To: 5.1.2e .5.1.2e 5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e 5.1.2e (5.1.2e)[5.1.2e @minvws.nl]; 5.1.2e .25.1.2e 5.1.2e)[5.1.2e 5.1.2e @minvws.nl]
From: 5.1.2e 5.1.2e (5.1.2e)e 5.1.2e)
Sent: Wed 3/31/2021 7:02:36 AM
Subject: FW: Celltrion Healthcare: Invitation to a Webinar COVID19 treatment
Received: Wed 3/31/2021 7:02:37 AM

Invitation to Celltrion webinar_April2021_updated.pdf

-----Oorspronkelijk bericht-----
Van: 5.1.2e 5.1.2e <5.1.2e@nost-korea.com>
Verzonden: woensdag 31 maart 2021 08:06
Aan: 5.1.2e ,1.5.1.2e (5.1.2e)' < 5.1.2e @rvo.nl>; 5.1.2e @rvo.nl; 5.1.2e ,5.1.2e.1.2. 5.1.2e (5.1.2e)' < 5.1.2e @rvo.nl>; 5.1.2e ,1.2. 1.2 5.1.2e (5.1.2e)' < 5.1.2e @rvo.nl>; 5.1.2e 5.1.2e (5.1.2e)e 5.1.2e) < 5.1.2e @minvws.nl>
CC: 5.1.2e < 5.1.2e @minbuza.nl>
Onderwerp: Celltrion Healthcare: Invitation to a Webinar COVID19 treatment

Dear all,

Last year, we have been in contact about getting covid related products (gloves, masks, ...) from Korea to the Netherlands.

Since the beginning of the outbreak, several Korean companies have been working on treatments. One of those companies is Celltrion. They are developing a "monoclonal antibody medicinal product" (CT-P59). It helps with preventing the progression to severe COVID-19 in patients with milder illness, and could potentially reduce the number of people who need ICU-hospitalization. This product of Celltrion is currently under review by the EMA.

Celltrion will organize a webinar about their CT-P59. For details of the program please see below. They are planning to hold this webinar on several days. Start time will always be 4pm Korea time, 9am Dutch time.

If you are interested to join, please inform 5.1.2e at 5.1.2e @celltrionhc.com

Please feel free to send this invitation to people who might be interested.

Best regards,
5.1.2e

From:
Sent: None
Subject: Greeting from Celltrion Healthcare: Invitation to a Webinar

Dear Sir/ Madam,

Hope all is going well with you.
This is 5.1.2e from Celltrion Healthcare HQ, South Korea.
We are currently developing monoclonal antibody medicinal product CT-P59 (regdanvimab, Brand name: Regkirona) for the treatment of patients with COVID-19.
As you probably know, regdanvimab has received Korean MFDS Conditional Marketing Authorisation, and currently being used for the patients in mild-to-moderate severity.
And also since regdanvimab is under rolling review by the EMA (https://www.ema.europa.eu/en/news/ema-starts-rolling-review-celltrion-antibody-regdanvimab-covid-19), we're expecting the marketing authorisation in Europe in the near future.

With growing global interest in regdanvimab, we hope to share Celltrion Healthcare's efforts and achievement so far via webinar.
So, We would like to invite you to our webinar titled "Regdanvimab webinar : Celltrion's efforts to respond to COVID-19".

In this webinar, we will share the non-clinical/ clinical results of regdanvimab, as well as our plans to respond to COVID-19 variants (UK, South Africa, etc.).
For more information of the event, please see below.

-- Information Details --
* Event Date : in April 2021 based upon responses & attendees, with duration of 80mins – The event will be held several times (2 to 4 times), Please inform us the preferred date among the candidates below.
- Date 1) 7th Apr. (Wed) / 16:00 – 17:20
- Date 2) 9th Apr. (Fri) / 16:00 – 17:20
- Date 3) 14th Apr. (Wed) / 16:00 – 17:20
- Date 4) 28th Apr. (Wed) / 16:00 – 17:20
* Agenda

- Title : Regdanvimab webinar : Celltrion's efforts to respond to COVID-19 Time Section Description
16:00 ~ 16:10
Welcome Introduction
* Company Introduction
* Brief Introduction of regdanvimab
16:10 ~ 16:20
Non-clinical study of regdanvimab
* Presentation of Non-clinical study
16:20 ~ 16:40
Clinical study of regdanvimab
* Presentation of clinical study results of Phase I, and Part 1 of Phase II/III
16:40 ~ 17:00
Novel therapeutic candidate
against emerging COVID-19 variants
* Development progress of cocktail treatment to cope with the COVID-19 variants and sharing of future plan
17:00 ~ 17:20
Q&A
-

* Target audience: Everyone who is interested in COVId-19 & therapeutic management
* Event type : Contactless (Online meeting, Microsoft teams)
- After collecting every preference from participants, the link of the meeting will be shared.

I sincerely look forward to meeting you soon online.
Thank you very much.

All the Best
5.1.2e

5.1.2e

Global Marketing Team
Medical and Marketing Dept.
CELLTRION HEALTHCARE CO.,LTD.
4F, Songdo-dong 19, 5.1.2e Yeonsu-gu, Incheon, South Korea 22014 5.1.2e
5.1.2e
E-mail: 5.1.2e @celltrionhc.com
_____
Help save paper! Do you really need to print this email?